Log in or register to see all Alerts
New HTA Decisions in Scotland
June 2020
Drug name
CYRAMZA® (ramucirumab)
Eli Lilly and Company Ltd
Decision date
Therapeutic area
Therapeutic sub area
Liver cancers
Not recommended
As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥400 ng/mL and who have been previously treated with sorafenib.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, ramucirumab (CYRAMZA®) is not recommended for use within NHS Scotland.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result the SMC cannot recommend its use within NHS Scotland.